Biotech Analyst Bullish on BIIB

[cnbc 3000028706]

Mark Schoenebaum, ISI Group analyst, explains how BIIB can triple its dividend in three years. “This growth exists nowhere else in large cap pharma or biotech,” he says.

Melissa Lee anchors a fast-paced discussion among four professional Wall Street traders. An hour after the bell Fast Money hosts one of the best trading discussions of the day.

Video © and provided by CNBC.

Be the first to comment

Leave a Reply